key: cord-1053944-qb9wluxd
authors: Mccoy, Jennifer A.; Short, William R.; Srinivas, Sindhu K.; Levine, Lisa D.; Hirshberg, Adi
title: Compassionate use remdesivir for treatment of severe COVID-19 in pregnant women at a United States academic center
date: 2020-06-25
journal: Am J Obstet Gynecol MFM
DOI: 10.1016/j.ajogmf.2020.100164
sha: ba87cf484dda64f0b0d838b83277b0d2e459a9da
doc_id: 1053944
cord_uid: qb9wluxd

nan

Patients were discharged prior to completion of the 10-day course if clinically 68 appropriate, in accordance with guidance from Gilead Sciences, Inc. 69

The manufacturer advises against breastfeeding while taking remdesivir given the 71 absence of information to confirm its safety. Patients who delivered during their 72 treatment course were advised to discard milk until treatment completed. 73 74 Results: 75 Table 1 summarizes key demographic and clinical characteristics. Figure 1 depicts 76 changes in ALT and AST values for each patient. Three required mechanical ventilation. 77

All five ultimately recovered to hospital discharge on room air. Two patients completed 78 the 10-day treatment course. Two were discharged prior to completion. One had 79 treatment halted due to elevated aminotransferases attributed to the medication. After 4 doses, she improved and was discharged. Her initial laboratory abnormalities 115 normalized (Figure 1 ). Five weeks later, she had an uncomplicated cesarean delivery of a 116 healthy infant. 117 

Compassionate Use of Remdesivir for 130 Patients with Severe Covid-19

Prophylactic and Therapeutic Remdesivir 132 (GS-5734) treatment in the Rhesus Macaque Model of MERS-CoV Infection

A randomized, controlled trial of Ebola 135 virus disease therapeutics

Gilead Sciences. Remdesivir (GS-5734) Investigator's Brochure

Ca 94404

Importance of inclusion of 139 pregnant and breastfeeding women in COVID-19 therapeutic trials

Figure 1. Aminotransferase levels by day of remdesivir therapy. Panel A: Alanine 191 aminotransferases (ALT)

Panel B: Aspartate aminotransferases (AST)

We describe our early experience using remdesivir for treatment of severe COVID-19 in 120